drugset

drugset / Trial / NCT06838676

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

NCT06838676 ↗

Phase 2 Recruiting 60 enrolled Nationwide Children's Hospital Accendatech USA Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.

Timeline

Start: 2025-07-10
Primary completion: 2028-07
Completion: 2035-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ACT001	Unknown	875 mg/m2	Oral

Indications